PeptiGen — AI platform for the development of peptide compounds with pharmalogical activity

Industry/Technology: AI (Artificial Intelligence), MedTech, Machine learning (ML), science and research, technologies

Region – Europe

Founded: 2022

Technology: AI, Biotechnology, Pharmaceuticals

Industry: MedTech

Problem solving

The PeptiGen platform generates unique peptide structures using artificial intelligence and machine learning methods. PeptiGen has made it possible to develop effective and investment-attractive compounds with antibacterial, antiviral and antitumor activity in vivo. PeptiGen's innovations are valuable for pharmaceutical companies, veterinary drug developers, cosmetology, cosmeceuticals, dietary supplement development, as well as for scientists and researchers in academic and educational institutions.

Value

  • Turnkey pharmaceuticals: development of innovative peptide compounds tailored to the client’s needs
  • Proof-of-concept for developed peptide compounds: validation of in vitro and in vivo efficacy
  • Variability: Over 30 peptides with different activities in our portfolio of molecules

Achievements

  • Investments from Mendeleev Venture Capital (since 2023)
  • Partnership with scientific development and production center Immunotex
  • Cooperation in the development of antitumor therapy with NMRC of Oncology